PCN137 EMPLOYMENT STATUS AND WORK-RELATED DIFFICULTIES IN LUNG CANCER SURVIVORS COMPARED WITH GENERAL POPULATION  by Kim, YA et al.
13th Euro Abstracts A277
of the time to symptom progression (TSP), time to deterioration (TTD) in trial 
outcome index (TOI), and time to deterioration (TTD) in QoL. An exploratory analy-
sis based on the time to analgesia and appearance of key symptoms (pain, cough, and 
dyspnea) was also performed. RESULTS: FACT-L completion rates were above 90% 
at almost all study visits. At baseline, QoL measures were similar between the two 
treatment groups. Maintenance therapy with erlotinib did not negatively impact on 
QoL, compared with placebo, as illustrated by comparable TSP (HR = 0.91 [0.74–
1.12], n = 785), TTD in TOI (HR = 1.06 [0.87–1.31], n = 781), or TTD in QoL (HR 
= 0.96 [0.79–1.16], n = 776). Exploratory analysis of NSCLC-related symptomatology 
showed that time to pain and time to analgesic use were signiﬁ cantly delayed in 
patients receiving erlotinib compared with placebo (HR = 0.61 [0.42–0.88]; P = 
0.0080 and HR = 0.66 [0.46–0.94]; P = 0.0199, respectively). There was also a 
nonsigniﬁ cant trend toward delayed time to cough and time to dyspnea (HR = 0.77 
[0.49–1.21] and HR = 0.75 [0.48–1.17], respectively). CONCLUSIONS: Erlotinib 
maintenance therapy signiﬁ cantly extends progression-free survival, without compro-
mising patient QoL and with some improvement in symptoms.
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OBJECTIVES: The aim of the EPICLIN-Lung study is to provide information on the 
impact and overall resource burden of the diverse strategies used across Europe for 
the management of NSCLC. Quality of life (QoL) and health state (HS) were deter-
mined by patient-reported outcome (PRO) questionnaires. METHODS: The EPI-
CLIN-Lung study (NCT00831909) is a noninterventional prospective cohort study 
conducted in Belgium, France, Germany, Greece, Italy, Portugal, Spain, and Turkey. 
Patients with conﬁ rmed NSCLC attending a participating clinical department for the 
ﬁ rst time between January and March 2009 were included. QoL and HS were assessed 
at baseline (Visit 1) by the responses to the PRO questionnaires FACT-L (Functional 
Assessment of Cancer Therapy-Lung) and EQ5D (EuroQoL-5D), respectively. 
RESULTS: Patients (N = 1500) received the questionnaires at Visit 1. QoL data werer 
available for 1500 patients and overall FACT-L mean score (±SD) was 93.4 (21.3). 
HS data were available for a total of 1402 patients, overall EQ5D mean score (±SD) 
was 63.3 (19.9). Mean scores (±SD) split by disease stage IIIb (FACT-L, n = 276; 
EQ5D, n = 258) and IV (FACT-L, n = 694; EQ5D, n = 653) were 93.5 (20.1) and 
91.3 (21.6) for FACT-L, respectively, and 64.2 (18.7) and 61.0 (20.5) for EQ5D, 
respectively. Mean scores (±SD) split by age <80 (FACT-L, n = 1,428; EQ5D, n = 
1,348) and age ≥80 (FACT-L, n = 61; EQ5D, n = 54) were 93.5 (21.4) and 92.9 (18.7) 
for FACT-L, respectively, and 63.5 (19.9) and 60.4 (19.9) for EQ5D, respectively. 
Mean scores (±SD) for patients with performance status 0, 1, 2, 3, and 4 were 100.9 
(18.7), 94.3 (21.3), 84.9 (20.9), 84.4 (21.0), and 85.0 (20.4), respectively, for FACT-L 
and 71.6 (17.6), 63.4 (19.3), 57.3 (17.9), 54.5 (21.3), and 55.0 (15.3), respectively, 
for EQ5D. CONCLUSIONS: This study provides a robust utility that could be used 
in the ﬁ nal analysis to assess the QoL and HS of NSCLC patients across Europe. More 
mature results and analysis will be provided at the meeting.
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DEALING WITH CULTURALLY SENSITIVE QUESTIONS IN THE COURSE 
OF TRANSLATING EORTC QUALITY-OF-LIFE GROUP 
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OBJECTIVES: The Translation Unit of the EORTC is responsible for coordinating 
new translations of HRQOL tools. According to the Translation Procedure described 
in the Translation Manual, one step is pilot-testing, involving 10 to 15 patients who 
comment on the new translation. This abstract’s aim is to review the difﬁ culties in 
translating sensitive issues (body image, death, etc.). METHODS: During the pilot 
testing, patients are interviewed about the translation, ﬁ lling in answer sheets. a report 
with their comments is reviewed by the Translation Unit. All questions with comments 
from at least two patients must be analyzed. The three possible reactions are to accept 
new translations suggested by the patients, to reword the English item, and provide a 
new translation or to provide no change (e.g., because the only solution would be to 
delete the item). Fifteen reports of QLQ-MY20 translations were analyzed. RESULTS: 
In the most recent 15 translations of QLQ-MY20, pilot-tested on 85 patients in 16 
countries, there were ﬁ ve language versions that caused no problem and 10 that 
received comments about offensiveness or disturbing nature of questions about body 
image and future perspectives (especially in countries such as China, Hong Kong, 
Thailand, Lebanon, where body image and death are taboos). All together, there were 
82 comments about four items (giving 20 translated questions causing difﬁ culties) 
which required thorough analysis and discussion. Results of the analysis included 
changing six translations (rewording, accepting patients’ suggestions), refusing ﬁ ve 
suggestions (they deviated from the source too much) and leaving nine translations 
without changes (since there were no suggestions and rewording was impossible). 
CONCLUSIONS: Scales concerning sexual functions, body image, and future perspec-
tives tend to raise concerns, especially in Asian and Arabic countries. However, such 
issues are resolved in the pilot-testing stage of the Translation Procedure through 
discussions, and linguistic and medical analyses of both source and target items.
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OBJECTIVES: The objective was to assess the improvement in quality-of-life out-
comes with interferon-alpha compared to sunitinib in treatment-naïve advanced/meta-
static renal cell carcinoma in patients. METHODS: Studies were retrieved from 
Embase, Pubmed, Cochrane, and DARE databases using relevant search strategies. 
Randomized controlled trials which compared IFN with sunitinib were included 
according to prespeciﬁ ed inclusion/exclusion criteria. The quality-of-life (QoL) data 
presented in the studies was independently extracted by two reviewers and differences 
were reconciled by a third reviewer. All studies were critically appraised and data was 
analyzed using STATA version 9.2. RESULTS: Of the 463 studies identiﬁ ed, three 
studies met the inclusion criteria. FKSI-DRS index was reported in one study with 
baseline and endpoint values as 29.55 and 27.4 with IFN-α and 29.74 and 29.4 with 
sunitinib (P < 0.0001). FKSI-15 index was reported in two studies with mean baseline 
and endpoint values as 46.1 and 42.1 with IFN-α and 46.45 and 45.3 with sunitinib 
(P < 0.0001). FACT-G score was reported in one study. The baseline FACT-G score 
was 81.25 with IFN-α and 82.3 with sunitinib. The endpoint FACT-G score was 76.8 
with IFN-α and 82.3 with sunitinib (P < 0.0001). EQ-5D score was reported in two 
of the included studies and was reported to be 0.76 and 0.73 as mean baseline and 
endpoint score for IFN-α group and 0.76 and 0.76 for sunitinib group. EQ-VAS score 
was reported in one study and was 71.43 and 68.7 as baseline and end point for IFN-α 
group and 73.8 and 73.4 for sunitinib group. The overall survival rate and response 
rate was better with sunitinib as compared to IFN-α. CONCLUSIONS: Improvement 
in quality-of-life outcomes was better in patients treated with IFN-α as compared to 
sunitinib at the end point. IFN-α continues to remain a treatment of choice despite of 
limited efﬁ cacy and tolerability.
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QUALITY OF LIFE AFTER CHEMOTHERAPY IN BREAST CANCER: A 
STUDY IN SOUTH OF IRAN
Ahmad Kiadaliri A1, Bastani P2
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OBJECTIVES: The aim of this study was to compare the impact of two common 
treatment of breast cancer on quality of life in women with early stage of breast cancer. 
METHODS: A double-blind cohort study was done in 100 breast cancer patients with 
node positive that used 5-ﬂ uorouracil, doxorubicin, cyclophosphamide (FAC) or 
docetaxel, doxorubicin, and cyclophosphamide (TAC) regimen as adjuvant therapies. 
Patients were followed for 4 months since end of chemotherapy. Health-related quality 
of life was assessed using questionnaire from European organization for research and 
treatment of cancer (EORTC) QLQ-C30. Independent t-test analysis was used at the 
signiﬁ cant level of 0.05 for analyzing the results. RESULTS: The mean of age was 
49.2911.59 and 46.718.23 years old in TAC and FAC groups, respectively. In the end 
of chemotherapy, QoL score were 64 and 68 in TAC and FAC groups, respectively 
(P < 0.005). After 4 months, patients in TAC and FAC groups experienced 11.45 and 
7.14 units improvement in QoL scores, respectively (P = 0.02). CONCLUSIONS: 
Although, TAC had a more negative impact on QoL during chemotherapy, it created 
a higher improvement than FAC during 4 months since end of treatment. These effects 
on quality of life should be considered in making decision for providing and ﬁ nancing 
cancer treatments in Iran.
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CANCER SURVIVORS COMPARED WITH GENERAL POPULATION
Kim YA1, Yun Y1, Zo JI1, Shim YM2
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OBJECTIVES: Although improved lung cancer survival is likely to result in increased 
lung cancer survivors, little was known about work situation among lung cancer 
survivors. The purpose of this study was to investigate employment status and work-
related difﬁ culties of lung cancer survivors compared with the general population. 
METHODS: We enrolled 917 lung cancer survivors from two hospitals 12 months 
after lung cancer surgery and 1000 volunteers from the general population. Multivari-
ate logistic regression was used to identify the factors associated with work situation. 
RESULTS: Employment decreased from 69.6% to 38.7% after cancer treatment. The 
proportion of lung cancer survivors who remained working was signiﬁ cantly smaller 
relative to that of the general population (63.5%) (adjusted odds ratio [aOR] = 2.59; 
95% conﬁ dence interval [CI]: 1.91 to 3.51). In subgroup analyses, female survivors 
over 65 years had unemployed after treatment (aOR = 89.24; 95%CI = 10.52 to 
756.91) than at the diagnosis of cancer. Among cancer survivor who remained 
employed after treatment (n = 284), 71.8% found no meaning of working and 15% 
experienced decrease wages. CONCLUSIONS: This is the ﬁ rst study with the largest 
number of patients investigating employment situation among lung cancer survivors 
reported poorer employment status than the general population. Among cancer sur-
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vivors, speciﬁ cally female survivors over 65 years had greater risk of work loss than 
general population. These ﬁ ndings should help working people concerned about 
employment after lung cancer. 
CANCER – Health-Care Use and Policy Studies
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HEALTH-CARE COSTS ASSOCIATED WITH BREAST CANCER 
MANAGEMENT
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OBJECTIVES: To assess the outpatient direct costs related to early and metastatic 
breast cancer (BC) management in Campania, a Southern Italy region. METHODS: 
This is a retrospective cohort study based on clinical records from 457 general prac-
titioners who managed an average of 630,000 inhabitants in Campania. Incident early 
BC cases from 2005 to 2007 were identiﬁ ed and costs related to outpatients manage-
ment were calculated until evidence of local recurrence or metastases (BC Event), 
death, revocation or the end of the database (December 31, 2009). For those patients 
who developed a BC event, costs for their disease management were further analyzed 
from the time of the event until death, revocation, or the end of the database. Monthly 
cost per patient was expressed in Euros. RESULTS: A total of 1529 patients with 
early BC were identiﬁ ed in the database. Of these, 112 women developed a BC event 
during the study period. At a median follow-up of 34 months, adjusted monthly 
primary care cost per patient was c151.87 in the subset of women with early BC. For 
those who experienced a BC event, at 24 months of follow-up, adjusted monthly 
primary care cost per patient was almost doubled: c289.15 (P < 0.0001). Main causes 
for this cost difference were related to increased number of specialists’visits, diagnostic 
procedures, and laboratory test once a BC event developed. CONCLUSIONS: Out-
patient’s management in women with metastatic BC is twice more expansive compared 
to management of women with early BC. Reasons for this increase are mainly due to 
increased frequency of imaging and diagnostic procedures in the metastatic BC subset. 
However, our study underestimates the total costs for metastatic BC patients’ manage-
ment because hospitalization and chemoptherapy costs are not included in our analy-
ses. Based on our data, secondary and tertiary prevention strategies must be signiﬁ cantly 
implemented in order to rationalize resource allocation.
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OBJECTIVES: Cancer patients from lower-income countries such as India often have 
limited access to modern medicines because of high costs. Using multiples of India’s 
per capita GDP as the threshold for economic value as suggested by the World Health 
Organization (WHO), decision analysis modeling was used to estimate a monthly cost 
for a hypothetical new cancer drug that provides a 3-month survival beneﬁ t to patients 
with metastatic colorectal cancer (mCRC). METHODS: A decision model was devel-
oped to simulate progression-free and overall survival in mCRC patients receiving 
chemotherapy ± the new drug. Outcomes for cancer control and side effects were 
obtained from randomized trials evaluating 1st and 2nd line chemotherapy in mCRC. 
Costs for chemotherapy were obtained from both public and private hospitals in India. 
Utility estimates measured as quality-adjusted life-years (QALY) were determined 
from 24 oncology nurses using the Time Trade-Off technique. These data were then 
used to estimate the monthly cost of the new drug using a threshold of $9300 per 
QALY gained, which is three times the Indian per capita GDP, as recommended by 
the WHO. RESULTS: The base-case analysis suggested that a monthly cost of $U.S.98 
would be considered cost-effective from the Indian public health-care perspective. If 
the drug were able to improve patient quality of life above the standard of care or 
survival from 3 to 6 months, the monthly drug cost could increase to $U.S.170 and 
$U.S.253 and offer the same value. CONCLUSIONS: The use of the WHO criteria 
for estimating a country-speciﬁ c drug price based on economic value for a developing 
country is feasible. However, the challenge would be to identify an appropriate 
threshold that would provide a balance between what patients/governments can afford 
to pay and the commercial viability of the product in the reference country.
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TRANSPARENCY OF DRUG REIMBURSEMENT IN POLAND—ONCOLOGY
Kujawska A, Nogas G
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OBJECTIVES: Increasing the level of transparency of decision-making process of 
reimbursement for drugs used in oncology by facilitating online access to public 
information and other information regarding the refund of cancer drugs in Poland 
compared to solutions used in the world. METHODS: The project will develop a 
comprehensive system to monitor the transparency of reimbursement decision-making 
process in Poland consisting of: Guidelines and Clinical and Reimbursement Recom-
mendations Database (WiRKliR database) whose purpose is to collect documents from 
the Polish and selected countries of the clinical guidelines, registration, and decisions 
about the recommendations and decisions regarding reimbursement for cancer drugs 
and present information contained in them in a comprehensible and transparent. 
Reimbursement monitoring which aims to carry out continuous monitoring of the 
implementation of law and regulation in the ﬁ eld of oncology drug reimbursement 
and the acquisition of complementary information about the cancer drugs in the 
database WiRKliR. Reimbursement reports whose purpose is to discuss the issue of 
transparency of reimbursement through the analysis of procedures drawn up and 
applied by public authorities in dealing with citizens, with special emphasis on patients 
and pharmaceutical companies in the reimbursement decision-making process and to 
present the results of the various stages of our work. RESULTS: The most important 
results of the project include: increased transparency of institutions involved in the 
drug reimbursement decision-making process, the democratization of medical infor-
mation, provide decision-makers Polish health-care system expertise, to increase 
patient awareness about their rights and proposals for corrective actions (conclusions 
and recommendations) for public administration in the area of the refund. CONCLU-
SIONS: A comprehensive monitoring system for civil funding allocation process in the 
health-care system to counteract the imbalance of information.
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WHAT IS THE CURRENT R&D LANDSCAPE FOR METASTATIC BREAST 
CANCER? AN INVESTIGATION INTO RECENT CLINICAL TRIAL 
ACTIVITY
Scrutton HC, Samuels ER
Heron Evidence Development Ltd, London, UK
OBJECTIVES: A number of systemic therapies are available for the treatment of 
metastatic breast cancer (MBC)—including hormonal therapies, chemotherapeutic 
agents, and biologics—but long-term prognosis remains poor. There is a need for new 
treatments that improve survival and are effective in a greater proportion of patients. 
This research evaluates the recent clinical trial activity directed toward the treatment 
of MBC. METHODS: MBC trials were identiﬁ ed through a systematic search of the 
records within http://www.clinicaltrials.gov, using the search term “metastatic breast 
cancer OR stage IV breast cancer OR advanced breast cancer.” Trials with a start 
date from January 2008 onward were included and categorized by nature of interven-
tion (new investigational agent, drug launched for indications other than breast cancer, 
or approved breast cancer product); all trials that did not include a pharmaceutical 
(biological or drug) were for an unsuitable indication, or that were suspended, termi-
nated, or withdrawn were excluded. The remaining trials were evaluated for a number 
of variables, including phase of development and product type. The overall number 
of pharmaceuticals under investigation was also explored. RESULTS: The original 
search term identiﬁ ed 2014 trials, 365 of which met the inclusion criteria. a large 
proportion of these trials (41%) were evaluating products already approved for the 
treatment of breast cancer. Of the remaining trials, 68% were investigating new 
agents; the remainders were evaluating a product launched for an indication other 
than breast cancer. There were a total of 116 new products under investigation, 
although these were mainly at an early stage of development with just 8% of trials at 
Phase III/IV. CONCLUSIONS: MBC is a key area of research, with a large number 
of products in development. However, since the majority of clinical trials are at an 
early stage, it will be some years before these products impact patient treatment.
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PRIMARY PREVENTION AS EXPANDED INDICATION TO MITIGATE 
COMPETITION: A CASE STUDY
Nichols E, Wiederkehr DP, Doyle J
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OBJECTIVES: While there are several instances of products gaining expanded indica-
tions from secondary treatment to primary treatment/prevention, in some cases, 
expanded indications appear to buffer the drug utilization from competitors. However, 
the extent to which the later expanded indications impact the utilization of the product 
across the lifecycle, including following loss of exclusivity, is not well understood. The 
objective was to examine the prescribing volume of a drug throughout its lifecycle in 
conjunction with the uptake of a novel class of drugs launched for similar indications 
to examine the impact of the expanded primary treatment/prevention indications on 
competition. METHODS: Tamoxifen and the aromatase inhibitors letrozole and anas-
trozole were selected as case products. All three drugs are FDA indicated for the 
treatment of advanced breast cancer, yet tamoxifen is the only drug of the group FDA 
indicated for the primary prevention of breast cancer. From January 1992 to April 
2010, the volume of prescriptions (TRx) was collected monthly using SDI’s VONA 
database and grouped according to class sales by active molecule. RESULTS: Generic 
sales of tamoxifen maintained a high level after the 1998 approval for the primary 
prevention indication of “reduction in breast cancer incidence in high-risk women” 
despite competition within active breast cancer treatment indications from the aroma-
tase inhibitors. While the aromatase inhibitors launched in the mid-1990s, their uti-
lization did not begin to encroach on total tamoxifen prescriptions until the expiration 
of exclusivity for tamoxifen’s prevention indication in 2003. CONCLUSIONS: This 
preliminary analysis shows that the strategy of obtaining a later primary prevention 
indication may help maintain utilization of a compound across the lifecycle. The 
hypothesis that a prevention indication expansion could mitigate competition should 
be further examined among products where primary prevention and primary treatment 
indications have distinctly different dosages and/or branding and where the additional 
indication is protected by extended exclusivity.
